

Isabel C Poschke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4496304/publications.pdf>

Version: 2024-02-01

15
papers

1,232
citations

623734

14
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

2655
citing authors

#	ARTICLE	IF	CITATIONS
1	Immature Immunosuppressive CD14+HLA-DR ^{hi} /low Cells in Melanoma Patients Are Stat3 ^{hi} and Overexpress CD80, CD83, and DC-Sign. <i>Cancer Research</i> , 2010, 70, 4335-4345.	0.9	366
2	On the armament and appearances of human myeloid-derived suppressor cells. <i>Clinical Immunology</i> , 2012, 144, 250-268.	3.2	168
3	Camouflage and sabotage: tumor escape from the immune system. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1161-1171.	4.2	150
4	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. <i>Oncotarget</i> , 2017, 8, 21539-21553.	1.8	103
5	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1240859.	4.6	75
6	A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1061-1071.	4.2	68
7	Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. <i>Blood</i> , 2022, 139, 142-147.	1.4	63
8	Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. <i>Oncolmmunology</i> , 2016, 5, e1052213.	4.6	51
9	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020, 26, 4289-4301.	7.0	46
10	A high-throughput <i>scRNA</i> screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. <i>EMBO Molecular Medicine</i> , 2015, 7, 450-463.	6.9	39
11	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. <i>Oncolmmunology</i> , 2020, 9, 1792058.	4.6	30
12	Next-generation TCR sequencing—A tool to understand T-cell infiltration in human cancers. <i>Journal of Pathology</i> , 2016, 240, 384-386.	4.5	25
13	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. <i>Frontiers in Immunology</i> , 2019, 10, 2766.	4.8	23
14	Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. <i>Science Signaling</i> , 2020, 13, .	3.6	18
15	Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. <i>Immunobiology</i> , 2014, 219, 189-197.	1.9	7